Novo Nordisk, Ventus Therapeutics collaborate for NLRP3 Inhibitor Program
Ventus retains the right to develop NLRP3 inhibitors for certain systemic diseases, including specific inflammatory and respiratory diseases.
Waltham, Mass.: Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, has announced that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates...
Waltham, Mass.: Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, has announced that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus' portfolio of peripherally-restricted NLRP3 inhibitors.
Read also: Novo Nordisk, Zealand Pharma collaborate for ZEGALOGUE for injection
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd